HRS 9531
Alternative Names: HRS-9531; KAI-9531Latest Information Update: 03 Jun 2025
At a glance
- Originator Fujian Shengdi Pharmaceutical
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
Most Recent Events
- 29 May 2025 Fujian Shengdi Pharmaceutical plans a phase III trial for Sleep apnoea syndrome and Obesity in China (SC, Injection) in June 2025 (NCT06994650)
- 16 May 2025 Fujian Shengdi Pharmaceutical plans a phase III trial for Sleep apnoea syndrome and Obesity in the China in May 2025 (Parenteral, Injection) (NCT06974851)
- 07 Apr 2025 Phase-II clinical trials in Obesity in China (PO) (NCT06841445)